We report a case of advanced sarcomatoid renal cell carcinoma (RCC) effectively treated with sunitinib. A 77-year-old female who had gross hematuria and left lower abdominal pain was found to have a left renal tumor by computed tomography (CT) and was referred to our hospital. CT revealed a poorly enhanced mass in the left kidney and an enlarged paraaortic lymph node. The patient underwent laparoscopic left nephrectomy, and the tumor was histologically diagnosed as a sarcomatoid RCC. Sunitinib was administered to treat lymph node metastasis, postoperatively, and a partial response was observed after 4 courses. Sunitinib administration has been continued without tumor re-growth.
Download full-text PDF |
Source |
---|
Cancer Treat Res Commun
January 2025
Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. Electronic address:
Clear cell renal cell carcinoma (ccRCC) poses a significant global health challenge as its incidence continues to rise, resulting in a substantial annual mortality rate. Major clinical challenges to current ccRCC treatments include high drug-resistance rates as well as dose-limiting adverse events; underlining the need to identify additional 'druggable' targets. TGF-β1, VEGF, and PD-L1 are potential therapeutic targets in ccRCC.
View Article and Find Full Text PDFZhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, School of Basic Medical Sciences, Peking University Third Hospital, Peking University Health Science Center, Beijing100191, China.
To understand the clinicopathological and molecular genetic characteristics of aggressive renal mucinous tubular and spindle cell carcinoma (MTSCC). The clinical features, histology, immunophenotype, molecular characteristics and prognosis of 4 cases of metastatic/recurrent renal MTSCC that were submitted to the Peking University Third Hospital (2 cases), Institute of Urology, Peking University (one case) and Zhejiang Provincial People's Hospital (one case) from 2015 to 2020 were retrospectively reviewed and analyzed. Among the four patients, two were male and two were female.
View Article and Find Full Text PDFEur Urol Open Sci
January 2025
Department of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Background And Objective: Our aim was to determine the clinical characteristics, temporal trends, and survival outcomes for sarcomatoid-dedifferentiated renal cell carcinoma (sRCC), as sRCC has historically had poor prognosis and a contemporary cohort has not been well characterized in a population-based study.
Methods: Data for 302 630 RCC cases from 2010 to 2019 were extracted from the National Cancer Data Base, of which 4.1% (12 329) were sRCC.
Cureus
December 2024
Department of Anatomopathology, Mohammed VI University Hospital/Faculty of Medicine, Mohammed 1st University, Oujda, MAR.
Sarcomatoid renal cell carcinoma (RCC) is an aggressive tumour with a poor prognosis. It is not a distinct histological entity, as it can be found in any subtype of renal cell carcinoma. The majority of cases will present with advanced or metastatic disease requiring systemic treatment.
View Article and Find Full Text PDFCureus
November 2024
Department of Obstetrics and Gynecology, Beaumont Hospital, Dearborn, USA.
Bladder cancer is one of the main causes of urogenital cancer (30-35% of the total urological cancers). Although metastases from urologic tumors are rare, it is associated with a high mortality rate. The location and pattern of metastasis are random and unpredictable.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!